A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine

被引：0
|
作者：
Kotoe Takayoshi
Kosuke Sagara
Keita Uchino
Hitoshi Kusaba
Naotaka Sakamoto
Atsushi Iguchi
Eishi Baba
机构：
[1] Clinical Research Institute,Department of Medical Oncology
[2] National Hospital Organization Kyushu Medical Center,Department of Medicine and Biosystemic Science
[3] Kyushu University Graduate School of Medical Sciences,Department of Urology
[4] National Hospital Organization Kyushu Medical Center,Department of Comprehensive Clinical Oncology
[5] Faculty of Medical Sciences,undefined
[6] Kyushu University,undefined
来源：
BMC Cancer | / 15卷
关键词：
ABCB1; Adverse event; Bile duct carcinoma; Gemcitabine; Plasma concentration; Renal cell carcinoma; Sunitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] RETRACTED: Metastatic collecting duct carcinoma of the kidney treated with sunitinib (Retracted Article)
    Tazi, El Mehdi
    Essadi, Ismail
    Fadl Tazi, Mohamed
    Ahellal, Youness
    M'rabti, Hind
    Errihani, Hassan
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2011, 9
  • [22] Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency
    Khan, G.
    Golshayan, A.
    Elson, P.
    Wood, L.
    Garcia, J.
    Bukowski, R.
    Rini, B.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1618 - 1622
  • [23] Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma
    Wentink, Madelon Q.
    Verheul, Henk M. W.
    Pal, Sumanta K.
    George, Saby
    Voortman, Johannes
    Danchaivijitr, Pongwut
    Adelaiye, Remi
    Poslinski, Diane
    Groman, Adrienne
    Hutson, Alan
    Pili, Roberto
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E1 - E9
  • [24] Onset of Male Gynaecomastia in a Patient Treated with Sunitinib for Metastatic Renal Cell Carcinoma
    Pierluigi Ballardini
    Guido Margutti
    Camillo Aliberti
    Roberto Manfredini
    Clinical Drug Investigation, 2009, 29 : 487 - 490
  • [25] Is There a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
    Keizman, Daniel
    Rouvinov, Keren
    Sella, Avishay
    Gottfried, Maya
    Maimon, Natalie
    Kim, Jenny J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria
    Peer, Avivit
    Carducci, Michael A.
    Mermershtain, Wilmosh
    Leibowitz-amit, Raya
    Weitzen, Rony
    Berger, Raanan
    CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 281 - 287
  • [26] Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib
    Bolzacchini, Elena
    Giordano, Monica
    Bertu, Lorenza
    Bregni, Marco
    Nigro, Olga
    Galli, Luca
    Antonuzzo, Andrea
    Artale, Salvatore
    Barzaghi, Sabrina
    Danova, Marco
    Torchio, Martina
    Pinotti, Graziella
    Dentali, Francesco
    TUMORI JOURNAL, 2022, 108 (05): : 502 - 509
  • [27] Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma
    Lim, Sung Hee
    Hwang, In Gyu
    Ji, Jun Ho
    Oh, Sung Yong
    Yi, Jun Ho
    Lim, Do Hyoung
    Lim, Ho Yeong
    Lee, Su Jin
    Park, Se Hoon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (01) : 61 - 67
  • [28] Sunitinib in Metastatic Renal Cell Carcinoma Patients With Brain Metastases
    Gore, Martin E.
    Hariharan, Subramanian
    Porta, Camillo
    Bracarda, Sergio
    Hawkins, Robert
    Bjarnason, Georg A.
    Oudard, Stephane
    Lee, Se-Hoon
    Carteni, Giacomo
    Nieto, Alejandra
    Yuan, Jinyu
    Szczylik, Cezary
    CANCER, 2011, 117 (03) : 501 - 509
  • [29] Alternate sunitinib schedules in patients with metastatic renal cell carcinoma
    Kalra, S.
    Rini, B. I.
    Jonasch, E.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1300 - 1304
  • [30] Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
    Beuselinck, B.
    Karadimou, A.
    Lambrechts, D.
    Claes, B.
    Wolter, P.
    Couchy, G.
    Berkers, J.
    Paridaens, R.
    Schoffski, P.
    Mejean, A.
    Verkarre, V.
    Lerut, E.
    de la Taille, A.
    Tourani, J-M
    Bigot, P.
    Linassier, C.
    Negrier, S.
    Berger, J.
    Patard, J-J
    Zucman-Rossi, J.
    Oudard, S.
    BRITISH JOURNAL OF CANCER, 2013, 108 (04) : 887 - 900
12345